CN204446846U - A kind of disposable per nasal brain-targeted drug delivery device - Google Patents
A kind of disposable per nasal brain-targeted drug delivery device Download PDFInfo
- Publication number
- CN204446846U CN204446846U CN201520122789.8U CN201520122789U CN204446846U CN 204446846 U CN204446846 U CN 204446846U CN 201520122789 U CN201520122789 U CN 201520122789U CN 204446846 U CN204446846 U CN 204446846U
- Authority
- CN
- China
- Prior art keywords
- conduit
- drug delivery
- delivery device
- targeted drug
- syringe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
Abstract
This utility model relates to a kind of disposable per nasal brain-targeted drug delivery device, comprise administrator, described administrator comprises conduit and is arranged on the fog-spray nozzle of one end of described conduit, described administrator also comprise there is inner chamber and syringe for depositing preparation, the other end of described conduit to be connected on described syringe and with the inner space of described syringe, described one end of described conduit can extend into the nasal cavity regio olfactoria of more than horizontal level corresponding to middle nasal concha through the meatus nasi communis of human body, described administrator also comprises for being isolated and the pressure sensitive film broken under pressure by the tube chamber of the inner chamber of described syringe and described conduit.Doser of the present utility model by preparation high-efficiency delivery to nasal cavity regio olfactoria, and then can absorb directly into brain, plays therapeutical effect central nervous system.
Description
Technical field
This utility model relates to a kind of disposable per nasal brain-targeted drug delivery device.
Background technology
Treat brain diseases as multiple sclerosis, parkinson disease, epilepsy, A Zihai silent disease, brain tumor, acquired immune deficiency syndrome (AIDS) and other infectious disease and acute poisoning time, medically there is a difficult problem always, that is: how blood brain barrier is overcome, medicine is entered rapidly in central nervous system (central nervous system, CNS) to play drug action.Applying more method clinically is at present open blood brain barrier by reversibility, and intrathecal injection and carotid injection administration, make agent permeates therethrough and enter central nervous system.But these methods require that in operating technology high, security risk is large, and application is subject to certain restriction.Based on the special construction of nasal cavity, by nasal-cavity administration treatment brain diseases have Noninvasive, brain bioavailability high, first passage metabolism and the advantage such as body circulation and blood brain barrier can be walked around, and handled easily.
In recent years, as long as much research all demonstrates by appropriate means, it is feasible that medicine directly enters brain by nasal cavity.Nasal cavity regio olfactoria is the position that in human body, unique place's neurocyte directly contacts with surrounding, by neurocyte (nervi olfactory, nervi trigeminus) path, intercellular substance path or all can realize the transmission of medicine per nasal Brain targeting with the blood capillary path that brain venous sinus is directly connected.But how medicine is sent as central nervous system by the approach of nasal cavity-brain effectively, and avoid too much directly absorption by nasal membrane to enter peripheral circulation and be one and have a difficult problem to be solved.
Existing large quantifier elimination focuses on the absorption efficiency being improved medicine per nasal-brain approach by the change of preparation, comprise methods such as increasing the particle diameter of medicine at the holdup time of nasal cavity, the permeability improving nasal membrane, drug molecule modification, change medicine, the permeability with liposome increase medicine, also form many patents.Patent CN101600417A discloses a kind of dopamine lid human relations gel preparation of nasal administration, the bioavailability that the per nasal Brain targeting improving medicine by lipotropy system absorbs.Patent CN102370623A discloses a kind of preparation method of liquid fatty substance microgranule for per nasal brain-targeted drug delivery.Patent CN102174080A discloses the polypeptide obtained by display technique of bacteriophage, for modified medicaments carrier to realize per nasal brain-targeted drug delivery effect.Patent CN1839799A discloses a kind of by Phytoagglutinin modified pharmaceutical carrier, to increase medicine holdup time in nasal cavity, thus realizes the method for per nasal brain-targeted drug delivery effect.Also patent is had to be conceived to be realized by doser the object of per nasal Brain targeting delivering drugs, patent CN201280021497 discloses a kind of nose medicine delivery apparatus, this device is intranasal form aerosolization by HFA Hydrofluoroalkane propellant, and by nozzle, medicine plume is delivered to nasal cavity regio olfactoria, thus being absorbed into brain, the ratio that its medicine enters regio olfactoria is more than 64.2%.
But nasal cavity regio olfactoria of the prior art doser also has following shortcoming: 1) although medicine can be delivered to nasal cavity regio olfactoria by the nozzle of doser, but nozzle can not extend into nasal cavity regio olfactoria, so medicine all can not be delivered to nasal cavity regio olfactoria, as in prior art, the medicine of about 64% can only be delivered to nasal cavity regio olfactoria, cause the waste of medicine, also can cause unnecessary economic loss to sufferer.2) doser is not pre-packaged design, each administration all needs powder charge again, makes up a prescription, operate more loaded down with trivial details, also lose time, particularly hospital's first aid, battlefield nerve gas removing toxic substances etc. are needed to the occasion of Quick medicine, probably can not can process in time sufferer because of the waste of powder charge, time of compounding.3) because each administration all needs the container again made up a prescription, administration makes storage of pharmaceutical to need often to open, easily make medicine occur rotten and can not use, particularly easily waste is caused for the medicine that some storage stabilities are low.4) each administration all will carry out the tedious steps that cleans, sterilize, if cleaning, sterilization thoroughly easily do not cause cross-contamination.
Summary of the invention
Technical problem to be solved in the utility model overcomes the deficiencies in the prior art, provides a kind of disposable per nasal brain-targeted drug delivery device.
For solving above technical problem, this utility model adopts following technical scheme:
A kind of disposable per nasal brain-targeted drug delivery device, comprise administrator, described administrator comprises conduit and is arranged on the fog-spray nozzle of one end of described conduit, described administrator also comprise there is inner chamber and syringe for depositing preparation, the other end of described conduit to be connected on described syringe and with the inner space of described syringe, described one end of described conduit can extend into the nasal cavity regio olfactoria of more than horizontal level corresponding to middle nasal concha through the meatus nasi communis of human body, described administrator also comprises for being isolated and the pressure sensitive film broken under pressure by the tube chamber of the inner chamber of described syringe and described conduit.
Further, described pressure sensitive film is arranged on the junction of described syringe and described conduit.
Further, described administrator also comprise be arranged on described conduit described one end, for cushioning the nasal cavity adapter of described conduit for the direct stimulation of nasal membrane.
The substantially tapered periphery being wrapped in described conduit of described nasal cavity adapter, the material of described nasal cavity adapter is selected from the one in medical silica-gel, neoprene, butadiene rubber, natural rubber, nitrile rubber, ethylene propylene diene rubber.
Further, described conduit is flexible pipe, and its external diameter is 0.1 ~ 50 millimeter.
The material of described conduit is selected from the one in medical silica-gel, latex, plastics, thermoplastic elastomer (TPE) (TPE).
Further, described fog-spray nozzle has the hole that the diameter of more than 1 or 1 is 0.1 ~ 1000 micron.
Preferably, the diameter in described hole is 1 ~ 100 micron.
Further, described syringe comprises the injection tube with described inner chamber and the piston be arranged in described injection tube, and described injection tube is provided with opening, and the described other end of described conduit connects over said opening.
Further, described doser also comprises the preparation of pre-packaged intracavity in described syringe.
Described preparation is can the preparation of direct administration.As this can directly administration preparation can for can directly administration powder preparation or also can be configured can the liquid type preparation of direct administration.
As described in preparation can be bioactive substance, described bioactive substance be selected from micromolecule non-peptide nonprotein medicine, peptide class/pharmaceutical grade protein, natural animal-plant and extract thereof, diagnostic agent one or more.
Described micromolecule non-peptide nonprotein medicine is selected from atropine and derivant thereof, pralidoxime, trimedoxime, obidoxime chloride, two pyridine monoxime, the two oxime of two pyridine, temozolomide (temozolomide), nitrosourea medicament, etoposide (etoposide), platinum medicine, irinotecan (irinotecan), capecitabine (capecitabine), methotrexate (methotrexate), gemcitabine (gemcitabine), topotecan (topotecan), cytosine arabinoside (cytarabine), thio-tepa (thiotepa), vincristine (vincristine), procarbazine (procarbazine), morphine, fentanyl, oxycodone, butorphanol, tramadol, granisetron, ondansetron, tropisetron, palonosetron, indisetron, sumatriptan, Zolmitriptan, rizatriptan, naratriptan, Ergotamine, triazolam, melatonin, carbamazepine, midazolam, donepezil, tiapride, cefaclor, enoxacin, acyclovir, zidovudine, didanosine, that Wei Laping, indinavir, dantrolene, digoxin, benzhexol, Biperiden, dextromethorphan, naloxone, betahistine, naphazoline, diltiazem, tranilast, loperamide, diclofenac, Beclomethasone, chlorpheniramine, sldenafil, Vardenafil, cobalamin, finasteride, epinephrine, 5-FU, low molecular weight heparin, one or more combination in tacrolimus.
Described peptide class/pharmaceutical grade protein is selected from insulin, growth hormone, somatostatin, growth hormone-releasing peptide, vasopressin, Desmopressin, vassopressin in spy, glucagon, calcitonin, interferon, erythropoietin, interleukin, parathyroid hormone (PTH1-34), parathyroid hormone (PTH1-84), parathyroid hormone PTH related peptides, GLP-1, vassopressin, leuprorelin, granulocyte colony-stimulating factor, prolactin antagonist, human menopausal gonadotropin, chorionic-gonadotropin hormone, follicle stimulating hormone, interstitialcellstimulating hormone (ICSH), leptin, Avastin (bevacizumab), Rituximab (rituximab), nerve growth factor, stem cell factor, keratinocyte growth factor, thioredoxin, one or more combination in cyclosporin and their analog.
Described natural animal-plant and extract thereof are selected from one or more the combination in Herba Asari, Borneolum Syntheticum, Radix Saposhnikoviae, Herba Schizonepetae, Radix Puerariae, Herba Hedyotidis Diffusae, Fructus Schisandrae Chinensis, Fructus Lycii, Rhododendron simsii Planch., Radix Sophorae Flavescentis, blue or green Semen Juglandis, rutin, Semen Ginkgo, Rhizoma Acori Graminei, Radix Ginseng, saponin, Cornu Cervi Pantotrichum, Herba Hyperici perforati, Radix Morindae Officinalis, Flos Albiziae, Radix Bupleuri, Radix Angelicae Sinensis, Herba Cistanches, Radix Scutellariae.
Described diagnostic agent is contrast agent.
Due to the enforcement of technique scheme, this utility model compared with prior art tool has the following advantages:
This utility model doser adopts disposable apparatus design, eliminates the repeated washing of doser, the tedious steps of sterilization, more reduces the potential risk of cross-contamination.
The conduit of this utility model doser can be deep into nasal cavity regio olfactoria, realizes brain-targeted drug delivery.
The conduit of this utility model doser is provided with fog-spray nozzle, and fog-spray nozzle makes it fogging fully and nasal cavity regio olfactoria nerve contact, improves the bioavailability of brain-targeted drug delivery.
Accompanying drawing explanation
Fig. 1 is the structural representation of this utility model doser;
Name in figure represented by numeral is called:
1, syringe; 101, injection tube; 102, piston; 2, conduit; 3, pressure sensitive film; 4, fog-spray nozzle; 5, hole; 6, nasal cavity adapter.
Detailed description of the invention
Below in conjunction with Figure of description, this utility model is further described.
As shown in Figure 1, a kind of disposable per nasal brain-targeted drug delivery device, comprise administrator, administrator comprises conduit 2 and is arranged on the fog-spray nozzle 4 of one end of conduit 2, administrator also comprise there is inner chamber and syringe 1 for depositing preparation, the other end of conduit 2 to be connected on syringe 1 and with the inner space of syringe 1, one end being provided with fog-spray nozzle 4 of conduit 2 can extend into the nasal cavity regio olfactoria of more than horizontal level corresponding to middle nasal concha through the meatus nasi communis of human body, administrator also comprises for being isolated and the pressure sensitive film 3 broken under pressure by the tube chamber of the inner chamber of syringe 1 and conduit 2.
In this example, pressure sensitive film 3 is arranged on the junction of syringe 1 and conduit 2.
Administrator of the present utility model also comprises the nasal cavity adapter 6 be arranged on one end being provided with fog-spray nozzle 4 of conduit 2, and nasal cavity adapter 6 is for cushioning the direct stimulation of conduit 2 for nasal membrane.Particularly, the tapered periphery being wrapped in conduit 2 of nasal cavity adapter 6, the material of nasal cavity adapter 6 is selected from the one in medical silica-gel, neoprene, butadiene rubber, natural rubber, nitrile rubber, ethylene propylene diene rubber.
Conduit 2 of the present utility model is flexible pipe, and its external diameter is 0.1 ~ 50 millimeter, and its material is selected from the one in medical silica-gel, latex, plastics, thermoplastic elastomer (TPE) (TPE).
The diameter that fog-spray nozzle 4 of the present utility model has more than 1 or 1 is the hole 5 of 0.1 ~ 1000 micron.Be preferably 1 ~ 100 micron.
In this example, syringe 1 comprises the injection tube 101 with inner chamber and the piston 102 be arranged in injection tube 101, and injection tube 101 is provided with opening, and one end of conduit 2 is connected on opening.
Doser of the present utility model also comprises the preparation of pre-packaged intracavity in syringe 1.Said preparation is can the preparation of direct administration.This can directly administration preparation can for can directly administration powder preparation or also can be configured can the liquid type preparation of direct administration.
In above-mentioned, preparation can be bioactive substance, bioactive substance be selected from micromolecule non-peptide nonprotein medicine, peptide class/pharmaceutical grade protein, natural animal-plant and extract thereof, diagnostic agent one or more.
The operation principle of this utility model doser:
The interior intracavity of syringe 1 deposited in by preparation, when needing administration, one end with fog-spray nozzle 4 of conduit 2 is extend into the nasal cavity regio olfactoria of more than horizontal level corresponding to middle nasal concha through the meatus nasi communis of human body, then piston 102 is inwardly promoted with hands, pressure sensitive film 3 is stressed to break, the inner chamber of syringe 1 is communicated with the tube chamber of conduit 2, preparation is delivered in conduit 2 by further push piston 102, then after fog-spray nozzle 4 is atomized, nasal cavity regio olfactoria is delivered to, and then directly suck brain, play therapeutical effect central nervous system.
Doser tool of the present utility model has the following advantages:
1) once daily device: doser adopts succinct design, and be easy to get and the material preparation of safety with relatively inexpensive, eliminate the repeated washing of doser, the tedious steps of sterilization, more reduce the potential risk of cross-contamination.
2) pre-packaged design: before use, make presser sensor film rupture by inside push piston thus the preparation deposited in the enclosure is directly used in administration, the process avoiding convenient administration device suction medicine to make up a prescription, is particularly useful for the occasion that hospital's first aid, battlefield nerve gas removing toxic substances etc. need Quick medicine.
3) conduit is used for nasal-cavity administration: due to human body rhinostenosis, general doser cannot probe into nasal meatus deep and carry out administration.Overwhelming majority medicine all cannot enter nasal cavity regio olfactoria, more cannot realize the administration object of nasal cavity Brain targeting.This utility model doser mixes the nasal cavity adapter of good biocompatibility, quality softness by conduit, make administering position can be deep into the horizontal level of meatus nasi communis close to nasal cavity regio olfactoria, substantially increase the targeting dosage that medicine enters regio olfactoria, local, avoid medicine enters peripheral circulation waste through Nasal Mucosa Absorption, also at utmost reduce the periphery side effect of medicine simultaneously.
4) the porous design of fog-spray nozzle: connect a fog-spray nozzle containing a large amount of micropore in catheter tip, necessarily injecting under pressure, by medicine aerosolization as much as possible, can make it fully and nasal cavity regio olfactoria nerve contact, improves the bioavailability of brain-targeted drug delivery.
5) injector designed: applied widely, is applicable to the situation of user self impotentia automedication as compared, as war wound soldier, handicapped patient, can assist dosing techniques by other people.
Above this utility model is described in detail; its object is to allow the personage being familiar with this art can understand content of the present utility model and be implemented; protection domain of the present utility model can not be limited with this; all equivalences done according to spirit of the present utility model change or modify, and all should be encompassed in protection domain of the present utility model.
Claims (9)
1. a disposable per nasal brain-targeted drug delivery device, comprise administrator, described administrator comprises conduit and is arranged on the fog-spray nozzle of one end of described conduit, it is characterized in that: described administrator also comprise there is inner chamber and syringe for depositing preparation, the other end of described conduit to be connected on described syringe and with the inner space of described syringe, described one end of described conduit can extend into the nasal cavity regio olfactoria of more than horizontal level corresponding to middle nasal concha through the meatus nasi communis of human body, described administrator also comprises for being isolated and the pressure sensitive film broken under pressure by the tube chamber of the inner chamber of described syringe and described conduit.
2. disposable per nasal brain-targeted drug delivery device according to claim 1, is characterized in that: described pressure sensitive film is arranged on the junction of described syringe and described conduit.
3. disposable per nasal brain-targeted drug delivery device according to claim 1, is characterized in that: described administrator also comprise be arranged on described conduit described one end, for cushioning the nasal cavity adapter of described conduit for the direct stimulation of nasal membrane.
4. disposable per nasal brain-targeted drug delivery device according to claim 1, it is characterized in that: described conduit is flexible pipe, its external diameter is 0.1 ~ 50 millimeter.
5. disposable per nasal brain-targeted drug delivery device according to claim 1, is characterized in that: the diameter that described fog-spray nozzle has more than 1 or 1 is the hole of 0.1 ~ 1000 micron.
6. disposable per nasal brain-targeted drug delivery device according to claim 5, is characterized in that: the diameter in described hole is 1 ~ 100 micron.
7. disposable per nasal brain-targeted drug delivery device according to claim 1, is characterized in that: described doser also comprises the preparation of pre-packaged intracavity in described syringe.
8. disposable per nasal brain-targeted drug delivery device according to claim 7, is characterized in that: described preparation is the one in micromolecule non-peptide nonprotein medicine, peptide class/pharmaceutical grade protein, natural animal-plant and extract thereof, diagnostic agent.
9. disposable per nasal brain-targeted drug delivery device according to claim 1, it is characterized in that: described syringe comprises the injection tube with described inner chamber and the piston be arranged in described injection tube, described injection tube is provided with opening, and the described other end of described conduit connects over said opening.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201520122789.8U CN204446846U (en) | 2015-03-03 | 2015-03-03 | A kind of disposable per nasal brain-targeted drug delivery device |
| PCT/CN2015/100090 WO2016138794A1 (en) | 2015-03-03 | 2015-12-31 | Disposable intranasal brain-targeting drug delivery apparatus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201520122789.8U CN204446846U (en) | 2015-03-03 | 2015-03-03 | A kind of disposable per nasal brain-targeted drug delivery device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN204446846U true CN204446846U (en) | 2015-07-08 |
Family
ID=53653798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201520122789.8U Active CN204446846U (en) | 2015-03-03 | 2015-03-03 | A kind of disposable per nasal brain-targeted drug delivery device |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN204446846U (en) |
| WO (1) | WO2016138794A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016138796A1 (en) * | 2015-03-03 | 2016-09-09 | 苏州同力生物医药有限公司 | Disposable intranasal brain-targeting drug delivery apparatus |
| WO2016138794A1 (en) * | 2015-03-03 | 2016-09-09 | 苏州同力生物医药有限公司 | Disposable intranasal brain-targeting drug delivery apparatus |
| CN111759720A (en) * | 2020-07-07 | 2020-10-13 | 上海长海医院 | Disposable nasal cleaning administration device |
| CN115282411A (en) * | 2022-01-14 | 2022-11-04 | 温州医科大学 | Delivery system for delivering drugs into the brain using the nasal olfactory region and method of use thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3865173A1 (en) * | 2020-02-14 | 2021-08-18 | Beiter GmbH & Co. KG | Nasal device |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4016126A1 (en) * | 1990-04-17 | 1991-10-24 | Coster Tecnologie Speciali Spa | DEVICE FOR TRANSNASAL OR ORAL ADMINISTRATION OF MEDICATIONS OR THE LIKE |
| CN2157789Y (en) * | 1993-02-13 | 1994-03-02 | 李治玖 | Atomization administrating injector |
| CN1607968A (en) * | 2001-11-02 | 2005-04-20 | 梅里迪安医学技术公司 | Medicament container, a medicament dispensing kit for administering medication and a method for packaging the same |
| EP2629820B1 (en) * | 2010-10-20 | 2019-08-07 | Teleflex Medical Incorporated | Miniature fluid atomizer |
| CN204446846U (en) * | 2015-03-03 | 2015-07-08 | 苏州同力生物医药有限公司 | A kind of disposable per nasal brain-targeted drug delivery device |
-
2015
- 2015-03-03 CN CN201520122789.8U patent/CN204446846U/en active Active
- 2015-12-31 WO PCT/CN2015/100090 patent/WO2016138794A1/en active Application Filing
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016138796A1 (en) * | 2015-03-03 | 2016-09-09 | 苏州同力生物医药有限公司 | Disposable intranasal brain-targeting drug delivery apparatus |
| WO2016138794A1 (en) * | 2015-03-03 | 2016-09-09 | 苏州同力生物医药有限公司 | Disposable intranasal brain-targeting drug delivery apparatus |
| CN111759720A (en) * | 2020-07-07 | 2020-10-13 | 上海长海医院 | Disposable nasal cleaning administration device |
| CN115282411A (en) * | 2022-01-14 | 2022-11-04 | 温州医科大学 | Delivery system for delivering drugs into the brain using the nasal olfactory region and method of use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016138794A1 (en) | 2016-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN204446846U (en) | A kind of disposable per nasal brain-targeted drug delivery device | |
| CN105228676B (en) | Include the medical treatment device of the vial adapter with inline dry kit | |
| CN105999486B (en) | Manual Diskus and its application in lung cancer therapy | |
| CN204446845U (en) | A kind of disposable per nasal brain-targeted drug delivery device | |
| CN204446844U (en) | Disposable per nasal brain-targeted drug delivery device | |
| CN107497036A (en) | A kind of intranasal medicator | |
| CN101947342A (en) | Drug administrator, drug administration device and drug administration method for nasal cavity mucous membrane | |
| CN204446847U (en) | A kind of disposable per nasal brain-targeted drug delivery device | |
| CN204745331U (en) | Breathe liquid medicine spraying device for internal medicine | |
| CN104667391B (en) | A kind of disposable intranasal brain-targeted drug delivery device | |
| CN106730188A (en) | A kind of Respiratory Medicine is atomized chemical spraying device | |
| CN114728123A (en) | Drug administration system configured to determine drug dosing regimen | |
| CN210472732U (en) | Medicine device is spouted with internal medicine to tuberculosis prevention and cure | |
| AU2011344958B2 (en) | Filtering powdered medicament inhaler and application | |
| CN208641520U (en) | A kind of nose spray drug delivery device | |
| CN115282411A (en) | Delivery system for delivering drugs into the brain using the nasal olfactory region and method of use thereof | |
| CN102553038B (en) | Medicine powder suction nozzle container | |
| CN204910350U (en) | Ware of dosing is fixed a position to anus intestines | |
| CN204840556U (en) | Medical atomizer mouth and medical atomizer | |
| CN205867296U (en) | Paediatrics nursing is with throat's ware of dosing | |
| CN104971414A (en) | Medicine sustained release device | |
| CN103316110A (en) | Use of medicine in simple schizophrenia treatment medicines | |
| CN103655108B (en) | A kind of child uses internal medicine nursing chair | |
| CN202061229U (en) | Nasal cavity vestibule dosing device | |
| CN211835668U (en) | Breathe internal medicine with spouting medicine device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |